To Evaluate the Safety and Efficacy of Repaglinide Plus Voglibose Combination in T2d Patients

M Kamran Khan, Firdous Shaikh

Abstract: Background: Type 2 diabetes mellitus (T2DM) requires effective glycemic control to prevent complications. Combining agents with complementary mechanisms may improve outcomes. Objective: To evaluate the safety and efficacy of the repaglinide plus voglibose combination in T2DM patients over one year. Methods: A prospective study was conducted involving 180 T2DM patients receiving repaglinide plus voglibose. Glycemic parameters, including fasting blood glucose (FBG), postprandial blood glucose (PPBG), and HbA1c, were measured at baseline and after 12 months. Safety was assessed by monitoring adverse events and hypoglycemic episodes. Results: Significant reductions were observed in mean FBG (156.8 ? 28.5 to 120.5 ? 22.3 mg/dL), PPBG (240.3 ? 35.7 to 170.7 ? 28.1 mg/dL), and HbA1c (8.2 ? 0.7 to 6.9 ? 0.6%) after 12 months (p < 0.001 for all). The combination was well tolerated, with mild hypoglycemia reported in 6.7% of patients and mild gastrointestinal side effects. Conclusion: Repaglinide plus voglibose combination therapy is effective and safe for improving glycemic control in T2DM patients, offering a viable option for optimizing diabetes management.

Keywords: Type 2 diabetes mellitus, Repaglinide, Voglibose, Combination therapy

How to Cite?: M Kamran Khan, Firdous Shaikh, "To Evaluate the Safety and Efficacy of Repaglinide Plus Voglibose Combination in T2d Patients", Volume 14 Issue 8, August 2025, International Journal of Science and Research (IJSR), Pages: 1085-1087, https://www.ijsr.net/getabstract.php?paperid=SR25820165226, DOI: https://dx.doi.org/10.21275/SR25820165226